Trial
NCT05199090
Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Obesity
Intervention
MBL949
Why stopped
The tolerability to benefit ratio based on maximum weight loss observed was not considered favorable at the doses studied and the study was terminated early
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-09